BioAtla (BCAB) risk factors, FY2025 10-K

Risks related to our financial position and need for additional capital

1. 01insufficient, we will not achieve profitability, which could have a material and adverse effect on our business, financial condition, results of operations and prospectsNew
2. 02We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts
3. 03We plan to use our existing cash and cash equivalents to fund the research and development of our product candidates and development programs and to fund working capital and other general corporate purposes26% rewritten
4. 04our efforts to enhance operational systems and attract and retain personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company
5. 05We invest a portion of our cash in a money market fund, which is vulnerable to market-specific risks that could adversely affect our business and financial condition

Risks related to the discovery, development and commercialization of our product candidates

1. 06varying interpretations of data by the FDA and comparable foreign regulatory authorities, including the EMA
2. 07Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities48% rewritten
3. 08We are substantially dependent on the success of our patented CAB technology platform, and our future success depends heavily on the successful development of this platform
4. 09We may not be successful in our efforts to use and expand our patented CAB technology platform to continue to build a pipeline of product candidates and develop marketable products
5. 10We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success
6. 11If the market opportunities for any product that we develop are smaller than we believe they are, our revenue may be adversely affected and our business may suffer
7. 12The market may not be receptive to our product candidates because they are based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates
8. 13Preliminary, preplanned interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
9. 14Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization of our product candidates
10. 15health epidemics and outbreaks, which in the past has resulted in, and in the future may result in, delays to patient enrollment, patients discontinuing their treatment or follow up visits or changes to trial protocols
11. 16Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control
12. 17Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences59% rewritten
13. 18ozuriftamab vedotin, evalstotug, and BA3182 have demonstrated manageable tolerability profiles thus far, we cannot assure you that these and our other product candidates will not cause more severe side effects in a greater proportion of patientsNew
14. 19our reputation may suffer
15. 20We are developing certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates85% rewritten
16. 21be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapiesNew
17. 22Our biologic product candidates for which we intend to seek approval may face competition through an abbreviated pathway
18. 23Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such failure could have a material and adverse effect on our business, financial condition, results of operations and prospects

Risks related to regulatory approval, other legal compliance matters and taxation

1. 24We are currently not in compliance with Nasdaq’s continued listing requirements. If we are unable to comply with Nasdaq’s continued listing requirements, our common stock could be delisted, which could affect the price of our common stock and liquidity and reduce our ability to raise capital
2. 25Our common stock is currently listed on The Nasdaq Capital Market. The Nasdaq Capital Market has established certain quantitative criteria and qualitative standards that companies must meet to remain listed for trading on this market99% rewritten
3. 26The Share Consolidation may not be sufficient to regain or maintain compliance with the Minimum Bid Price Requirement, and the re-pricing mechanism contained in our outstanding warrants may substantially limit the proceeds we receive from the exercise of such warrants following the Share ConsolidationNew
4. 27We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates84% rewritten
5. 28we or our contractors may not meet the current Good Manufacturing Practices (“cGMPs”) and other applicable requirements for manufacturing processes, procedures, documentation and facilities necessary for approval by the FDA or comparable foreign regulatory authorities38% rewritten
6. 29If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivityNew
7. 30injunctions or the imposition of civil or criminal penalties
8. 31Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
9. 32The FDA and other comparable foreign regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses32% rewritten
10. 33The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
11. 34Healthcare legislative reform measures may have a material adverse effect on our business and results of operations94% rewritten
12. 35addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirementsNew
13. 36If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business
14. 37Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing37% rewritten
15. 38We and our third-party contractors must comply with environmental, health and safety laws and regulations. A failure to comply with these laws and regulations could expose us to significant costs or liabilities
16. 39Changes in tax laws or in their implementation or interpretation may adversely affect us or our investors54% rewritten

Risks related to the formal process to explore and evaluate strategic options

1. 40We have initiated a formal process to explore and evaluate strategic options, and there is no guarantee that this strategic path will be successfulNew
2. 41If we are unable to successfully complete a strategic transaction, we may be forced to cease operations altogether or file for bankruptcy protectionNew
3. 42We may not realize any additional value in a strategic transactionNew
4. 43If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risksNew
5. 44We may not fully realize the expected cost savings and/or operating efficiencies from our restructuring activities and our ability to consummate a strategic transaction depends on our ability to retain our employees required to consummate such transactionNew
6. 45Transactions that we have previously entered into may be re-evaluated or restructured as part of the strategic process, and there can be no assurance that clinical development of our programs will not be limited or delayed as a result of the strategic processNew

Risks related to employee matters, managing our growth and other risks related to our business

1. 46If we fail to attract and retain qualified senior management and key clinical and scientific personnel, our business may be materially and adversely affected
2. 47We currently have no sales organization. If we are unable to establish sales, marketing and distribution capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue
3. 48In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth
4. 49improving our operational, financial and management controls, reporting systems and procedures25% rewritten
5. 50Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements26% rewritten
6. 51Our current operations are concentrated in one location. We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
7. 52Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally
8. 53business interruptions resulting from geo-political actions, including war and terrorism68% rewritten
9. 54We face risks related to health epidemics and outbreaks, which could significantly disrupt our preclinical studies, affect enrollment of patients in our clinical trials or delay or prevent our receipt of necessary regulatory approvals
10. 55We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures. We are complying with all applicable guidelines for our clinical trials, including remote clinical monitoring

Risks related to our dependence on third parties

1. 56collaborators and other alliances could independently develop, or develop with third parties, products that compete directly or
2. 57collaborators’ sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings
3. 58We may not be successful in establishing commercialization collaborations, which could adversely affect our ability to commercialize our product candidates, if approved
4. 59the misappropriation of our proprietary information, including our trade secrets and know-how

Risks related to intellectual property

1. 60We may obtain, maintain, protect and enforce intellectual property protection for our technologies and product candidates
2. 61Our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our commercial markets
3. 62If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
4. 63The terms of our patents may not protect our competitive position on our product candidates for an adequate amount of time
5. 64If we do not obtain patent term extension for our product candidates, our business may be materially harmed
6. 65Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents
7. 66Changes in U.S. patent law or laws in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
8. 67Other companies or organizations may challenge our or our licensors’ patent rights or may assert patent rights that prevent us from developing and commercializing our products
9. 68We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products
10. 69We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
11. 70We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful, and issued patents covering our product candidates could be found invalid or unenforceable if challenged in court in the United States or abroad
12. 71We may not be able to protect our intellectual property rights throughout the world
13. 72Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
14. 73If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses
15. 74We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses
16. 75Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
17. 76If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks related to our common stock

1. 77Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
2. 78changes in general market and economic conditions
3. 79Our stock price may be volatile, and you could lose all or part of your investment
4. 80general economic, industry and market conditions
5. 81The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital20% rewritten
6. 82If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline
7. 83Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval and their interests may conflict with your interests as an owner of our common stock
8. 84Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
9. 85Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
10. 86the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine
11. 87The Company’s ability to attract and retain qualified members of our board of directors may be impacted due to new laws, including recently enacted diversity quotas
12. 88Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
13. 89Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock
14. 90We may be subject to securities litigation, which is expensive and could divert our management’s attention